Gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: Final results of a phase II study No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results